- Research
- Cancer Biomarkers and Therapeutics
- Ana Silva
Ana Silva
- Oncobiology
- biochemistry
- bladder cancer
- aggressive cancers
- targeted therapies
- cell biology
Ana Silva is graduated in Biology and Geology by the University of Minho, and holds a Master’s degree in Applied Biochemistry, with specialization in Biomedicine, by the same University, with a final score of 18 (out of 20). Ana has been a researcher at the Life and Health Sciences Research Institute (ICVS), University of Minho, for three years, focusing her research in unraveling new therapeutic options for aggressive solid tumors. Between 2020 and 2022, she developed her master’s thesis project (score 19 out of 20), entitled “Pre-clinical pharmacology of the monocarboxylate transporter 1 inhibitor AZD3965 in bladder cancer”, supervised by Dr. Julieta Afonso and co-supervised by Dr. Ana Preto. This project aimed to evaluate the anticancer activity of AZD3965, a specific MCT1 inhibitor, in muscle-invasive bladder cancer cell lines. She acquired practice in several in vitro techniques (cell culture, RT-qPCR, immunofluorescence, Western Blot) and biological functional assays . Additionally, she acquired expertise in in vivo assays, such as the CAM model assay, and holds FELASA certification for animal experimentation. Additionally, she was awarded a PhD scholarship in 2022 funded by FCT, and is currently undergoing her PhD in Health Sciences at the same institution. During her academic path, Ana has published 3 scientific papers (systematic reviews and experimental) and has presented several conference posters in national and international conferences.
Ana Silva
- Oncobiology
- biochemistry
- bladder cancer
- aggressive cancers
- targeted therapies
- cell biology
Ana Silva is graduated in Biology and Geology by the University of Minho, and holds a Master’s degree in Applied Biochemistry, with specialization in Biomedicine, by the same University, with a final score of 18 (out of 20). Ana has been a researcher at the Life and Health Sciences Research Institute (ICVS), University of Minho, for three years, focusing her research in unraveling new therapeutic options for aggressive solid tumors. Between 2020 and 2022, she developed her master’s thesis project (score 19 out of 20), entitled “Pre-clinical pharmacology of the monocarboxylate transporter 1 inhibitor AZD3965 in bladder cancer”, supervised by Dr. Julieta Afonso and co-supervised by Dr. Ana Preto. This project aimed to evaluate the anticancer activity of AZD3965, a specific MCT1 inhibitor, in muscle-invasive bladder cancer cell lines. She acquired practice in several in vitro techniques (cell culture, RT-qPCR, immunofluorescence, Western Blot) and biological functional assays . Additionally, she acquired expertise in in vivo assays, such as the CAM model assay, and holds FELASA certification for animal experimentation. Additionally, she was awarded a PhD scholarship in 2022 funded by FCT, and is currently undergoing her PhD in Health Sciences at the same institution. During her academic path, Ana has published 3 scientific papers (systematic reviews and experimental) and has presented several conference posters in national and international conferences.
Scientific Highlights
Papers:
Silva A, Antunes B, Batista A, Pinto-Ribeiro F, Baltazar F, Afonso J. In Vivo Anticancer Activity of AZD3965: A Systematic Review. Molecules. 2021 Dec 29;27(1):181. doi: 10.3390/molecules27010181.
Silva, A.; Cerqueira, M.C.; Rosa, B.; Sobral, C.; Pinto-Ribeiro, F.; Costa, M.F.; Baltazar, F.; Afonso, J. Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 5141. doi.org/10.3390/ijms24065141
Silva, A.; Félix, A.; Cerqueira, M.; Gonçalves, C.S.; Sampaio-Marques, B.; Longatto-Filho, A.; Baltazar, F.; Afonso, J. Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer. Pharmaceutics 2023, 15, 2688. doi.org/10.3390/pharmaceutics15122688
Conference Posters:
Silva, A; Félix, A; Cerqueira, M; Gonçalves, CS; Sampaio-Marques, B; LongattoFilho, A; Baltazar, F; Afonso, J. “Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer”. Paper presented in III ASPIC/ASEICA International Meeting, 2023.
Silva, A; Cerqueira, MC; Rosa,B; Sobral, C; Pinto-Ribeiro, F; Costa, MF; Baltazar, F; Afonso, J. “Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review”. Paper presented in Porto Cancer Meeting, 2023.
M Cequeira; E Belmonte-Reche; C Gonçalves; M Costa; R Rainha; A Silva; F Baltazar; J Gallo; M Bañobre. “Treatment of triple-negative breast cancer through externally triggered target-less drug carriers”. Paper presented in Porto Cancer Meeting, 2023.
Silva, Ana; Félix, Ana; Gonçalves, Céline; Baltazar, Fátima; Afonso, Julieta. “Preclinical pharmacology of the monocarboxylate transporter 1 inhibitor AZD3965 in bladder cancer”. Paper presented in 4ª Encontro Nacional de Jovens Investigadores em Oncologia, 2022.
Silva, Ana; Félix, Ana; Gonçalves, Céline; Baltazar, Fátima; Afonso, Julieta. “Preclinical pharmacology of the monocarboxylate transporter 1 inhibitor AZD3965 in bladder cancer”. Paper presented in Porto Cancer Meeting, 2022.
Add Your Heading Text Here
Contact us
Phone: +351 253 604 967
Fax: +351 253 604 809
Email: icvs.sec@med.uminho.pt
Address
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Copyright ©2022 ICVS. All Rights Reserved
Address
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Address
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal